Isaac Cheng
Investment Professional @ Morningside
Isaac Cheng is a Series B investor at Morningside focused on Medical and Biotechnology. Dr. Cheng of Morningside Technology Advisory LLC focuses on life science and technology investments. Prior to joining Morningside, Dr. Cheng was Director of Research and Development at Serica Technologies, a Morningside portfolio company. In addition, Dr. Cheng was previously an Associate Director at Novartis Pharmaceuticals in Clinical Developmentand Medical Affairs. Dr. Cheng received his M.D. from Tufts University School of Medicine. He is the recipient of numerous honors and awards including the Howard Hughes Medical Institute Research Fellowship, which supported his research under Dr. Rudy Tanzi in the Genetics and Aging Unit of the Massachusetts General Hospital / Harvard Medical School. He has worked with many start ups and currently sits on the Board of Directors of Traversa Therapeutics and is a board observer to Argos Therapeutics.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 50%
Last updated:
For AI agents: llms.txt
Industries Isaac Cheng invests in
Stages Isaac Cheng invests in
Countries Isaac Cheng invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Medical 5 (42%)
- Biotechnology 5 (42%)
- Health Care 4 (33%)
- Pharmaceutical 3 (25%)
- Therapeutics 2 (17%)
Stage
- Series B 6 (50%)
- Series C 4 (33%)
- Series A 1 (8%)
Country
- United States 6 (50%)
- United Kingdom 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Apnimed
|
Apnimed is a clinical-stage company dedicated to the discovery of novel pharmacologic therapies for sleep apnea and related disorders.Sleep apnea is a common, serious condition with significant morbidity, increased mortality, and substantial effects on daily functioning. Sleep apnea affects more than 20 million Americans and has seriousconsequences. OSA is caused by a combination of predisposing anatomical factors and sleep-related decrements of activity in upper airway muscles.Current treatments primarily rely on positive pressure devices, e.g., CPAP, to maintain airway patency. Less commonly used treatments include mandibular advancement devices, nerve stimulation, and surgical interventions.Apnimed, Inc. was founded in 2017 and is located in Cambridge, Massachusetts. | $62.5M / Series C / May 04, 2022 | |
Big Health
|
Big Health is a digital therapeutics company that operates a digital healthcare portal to offer fully-automated and highly personalized digital therapeutics and behavioral programs for mental health issues. Its portal offers an online personalized medicine-care and prepares a sleep improvement program in consultation with medical professionals thatenable individuals to overcome their sleep-related disorders in an efficient manner. | $75M / Series C / Jan 19, 2022 | |
|
Big Health
|
Big Health is a digital therapeutics company that operates a digital healthcare portal to offer fully-automated and highly personalized digital therapeutics and behavioral programs for mental health issues. Its portal offers an online personalized medicine-care and prepares a sleep improvement program in consultation with medical professionals thatenable individuals to overcome their sleep-related disorders in an efficient manner. | $75M / Series C / Jan 19, 2022 | |
Amylyx Pharmaceuticals
|
Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain. The company features a drug designed to prevent nerve cell death and degeneration. Amylyx Pharmaceuticals was founded in 2014 and headquartered in Massachusetts, United States. | $135M / Series C / Jul 20, 2021 | |
Revolo Biotherapeutics
|
Revolo Biotherapeutics has developed therapies that achieve superior long-term disease remission from less frequent chronic dosing and without suppression of the immune system. Its mission is to revolutionize autoimmune and allergic disease treatment by resetting the immune system for superior long-term disease remission.Revolo Biotherapeuticswas founded in 2011 and formerly known as Immune Regulation. | $52M / Series B / Sep 21, 2020 | |
|
Amylyx Pharmaceuticals
|
Amylyx Pharmaceuticals specializes in providing solutions for Alzheimer’s and other diseases of the brain. The company features a drug designed to prevent nerve cell death and degeneration. Amylyx Pharmaceuticals was founded in 2014 and headquartered in Massachusetts, United States. | $30M / Series B / Jul 01, 2020 | |
|
Big Health
|
Big Health is a digital therapeutics company that operates a digital healthcare portal to offer fully-automated and highly personalized digital therapeutics and behavioral programs for mental health issues. Its portal offers an online personalized medicine-care and prepares a sleep improvement program in consultation with medical professionals thatenable individuals to overcome their sleep-related disorders in an efficient manner. | $39M / Series B / Jun 18, 2020 | |
Advanced Cell Diagnostics
|
Advanced Cell Diagnostics (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry. | $22M / Series C / Jun 18, 2015 | |
|
Advanced Cell Diagnostics
|
Advanced Cell Diagnostics (ACD) is a leader in the emerging field of molecular pathology, developing cell- and tissue-based diagnostic tests for personalized medicine. Based in the heart of Silicon Valley, ACD was founded and managed by experienced entrepreneurs in the life science industry. | Series B / Nov 01, 2012 | |
Traversa Therapeutics
|
Traversa Therapeutics, Inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of RNAi Delivery Technologies. The company strives to rapidly advance short interfering RNA (siRNA) platform delivery technologies for use by RNAi therapeutic companies in targeting a wide variety of acute, chronic and infectioushuman diseases. Traversa is focused on the optimization of this platform delivery technology, as well as advancement of its own therapeutic programs for the treatment of Leukemia and Glioblastoma. | $5M / Series B / Apr 07, 2009 | |
| See all 12 investments → | |||
Co-Investors
About Morningside
Morningside makes venture capital investments in companies with novel science and technology. We are characterized by a long-term outlook in company-building and an unwavering commitment to acting ethically. Based in the greater Boston area, our team of entrepreneurial investment professionals has deep experience in life sciences, digital health,AI, materials and technology. Founded in 1986 as a family office for the Chan family, charitable commitments to education, research and healthcare include the Harvard T.H. Chan School of Public Health, the UMass Chan Medical School, and the MIT Morningside Academy for Design.
Morningside Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Gerald Chan
Co-founded
|
|||
|
Isaac Cheng
Investment Professional
|
|||
Richard Liu
General Partner
|
|||
Ronnie Chan
Co-founder
|
|||
Stephanie O'Brien
Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Isaac Cheng invest in?
Isaac Cheng invests primarily in Medical, Biotechnology and Health Care startups, most often at Series B and Series C stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Isaac Cheng?
Public channels for Isaac Cheng include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Isaac Cheng last invest?
The most recent investment recorded for Isaac Cheng closed in May 2022. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
